Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

p53-independent structure-activity relationships of 3-ring mesogenic compounds’ activity as cytotoxic effects against human non-small cell lung cancer lines

Authors: Saori Fukushi, Hironori Yoshino, Atsushi Yoshizawa, Ikuo Kashiwakura

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

We recently demonstrated the cytotoxicity of liquid crystal precursors (hereafter referred to as “mesogenic compounds”) in the human non-small cell lung cancer (NSCLC) cell line A549 which carry wild-type p53. p53 mutations are observed in 50 % of NSCLC and contribute to their resistance to chemotherapy. To develop more effective and cancer-specific agents, in this study, we investigated the structure–activity relationships of mesogenic compounds with cytotoxic effects against multiple NSCLC cells.

Methods

The pharmacological effects of mesogenic compounds were examined in human NSCLC cells (A549, LU99, EBC-1, and H1299) and normal WI-38 human fibroblast. Analyses of the cell cycle, cell-death induction, and capsases expression were performed.

Results

The 3-ring compounds possessing terminal alkyl and hydroxyl groups (compounds C1–C5) showed cytotoxicity in NSCLC cells regardless of the p53 status. The compounds C1 and C3, which possess a pyrimidine at the center of the core, induced G2/M arrest, while the compounds without a pyrimidine (C2, C4, and C5) caused G1 arrest; all compounds produced caspase-mediated cell death. These events occurred in a p53-independent manner. Furthermore, it was suggested that compounds induced cell death through p53-independent DNA damage-signaling pathway. Compounds C2, C4, and C5 did not show strong cytotoxicity in WI-38 cells, whereas C1 and C3 did. However, the cytotoxicity of compound C1 against WI-38 cells was improved by modulating the terminal alkyl chain lengths of the compound.

Conclusions

We showed the p53-indepdent structure–activity relationships of mesogenic compounds related to the cytotoxic effects. These structure–activity relationships will be helpful in the development of more effective and cancer-specific agents.
Appendix
Available only for authorised users
Literature
1.
Tsai MF, Wang CC, Chen JJ. Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer. World J Clin Oncol. 2014;5:865–73.CrossRefPubMedPubMedCentral
2.
Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009;9:17–35.CrossRefPubMed
3.
Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol. 2009;39:137–50.CrossRefPubMed
4.
Park SY, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer. 2010;9:222.CrossRefPubMedPubMedCentral
5.
6.
Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332:237–48.CrossRefPubMed
7.
Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 2005;17:631–6.CrossRefPubMed
8.
Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr AJ, Magrath I, Kohn KW, O’Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994;54:5824–30.PubMed
9.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–9.CrossRefPubMedPubMedCentral
10.
Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 2007;67:1163–9.CrossRefPubMed
11.
Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2011;71:7071–9.CrossRefPubMedPubMedCentral
12.
Aurelio ON, Cajot JF, Hua ML, Khwaja Z, Stanbridge EJ. Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions. Cancer Res. 1998;58:2190–5.PubMed
13.
Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996;15:827–38.PubMedPubMedCentral
14.
Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331:868–80.CrossRefPubMed
15.
Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75:173–234.CrossRefPubMedPubMedCentral
16.
Stevenson CL, Bennett DB, Lechuga-Ballesteros D. Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci. 2005;94:1861–80.CrossRefPubMed
17.
Cervin C, Vandoolaeghe P, Nistor C, Tiberg F, Johnsson M. A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers. Eur J Pharm Sci. 2009;36:377–85.CrossRefPubMed
18.
Wang M, Gartel AL. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther. 2011;10:2287–97.CrossRefPubMedPubMedCentral
19.
Terasawa R, Fukushi Y, Monzen S, Miura T, Takahashi K, Yoshizawa A, Kashiwakura I. The promoting activity on human megakaryocytopoiesis and thrombopoiesis by liquid crystal-related compounds. Biol Pharm Bull. 2009;32:976–81.CrossRefPubMed
20.
Takahashi Y, Hazawa M, Takahashi K, Nishizawa A, Yoshizawa A, Kashiwakura I. Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line. Invest New Drugs. 2011;29:659–65.CrossRefPubMed
21.
Fukushi Y, Hazawa M, Takahashi K, Yoshizawa A, Kashiwakura I. Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line. Invest New Drugs. 2011;29:827–32.CrossRefPubMed
22.
Wakasaya T, Yoshino H, Fukushi Y, Yoshizawa A, Kashiwakura I. A liquid crystal-related compound induces cell cycle arrest at the G2/M phase and apoptosis in the A549 human non-small cell lung cancer cell line. Int J Oncol. 2013;42:1205–11.PubMed
23.
Fukushi Y, Yoshino H, Ishikawa J, Sagisaka M, Kashiwakura I, Yoshizawa A. Synthesis and anticancer properties of phenyl benzoate derivatives possessing a terminal hydroxyl group. J Mater Chem B. 2014;2:1335–43.CrossRef
24.
Yoshino H, Saitoh T, Kozakai M, Kashiwakura I. Effects of ionizing radiation on retinoic acid-inducible gene-I-like receptors. Biomed Rep. 2015;3:59–62.PubMed
25.
Yanai H. Statcel-the useful add-in software forms on Excel. 3rd ed. Tokyo: OMS; 2011.
26.
Arnott JA, Kumar R, Planey SL. Lipophilicity indices for drug development. J Appl Biopharm Pharmacokinet. 2013;1:31–6.
27.
28.
Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999;59:4375–82.PubMed
29.
Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261–91.CrossRefPubMed
30.
31.
32.
Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene. 2002;21:8414–27.CrossRefPubMed
33.
Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012;19:42–50.CrossRefPubMed
34.
Hasegawa A, Cheng X, Kajino K, Berezov A, Murata K, Nakayama T, Yagita H, Murali R, Greene MI. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A. 2004;101:6599–604.CrossRefPubMedPubMedCentral
35.
Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013;20:648–59.CrossRefPubMed
36.
Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506.CrossRefPubMed
37.
Maliepaard M, de Mol NJ, Janssen LH, van der Neut W, Verboom W, Reinhoudt DN. Role of lipophilicity in the in vitro antitumour activity of a series of new mitosene compounds. Anticancer Drug Des. 1992;7:415–25.PubMed
38.
Supek F, Ramljak TŠ, Marjanović M, Buljubašić M, Kragol G, Ilić N, Smuc T, Zahradka D, Mlinarić-Majerski K, Kralj M. Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns. Eur J Med Chem. 2011;46:3444–54.CrossRefPubMed
39.
Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer. 2007;7:107–17.CrossRefPubMed
40.
41.
Marzo I, Naval J. Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Biochem Pharmacol. 2013;86:703–10.CrossRefPubMed
42.
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194–204.CrossRefPubMed
43.
Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007;8:379–93.CrossRefPubMed
44.
Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaccone G. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res. 2000;6:203–12.PubMed
45.
46.
47.
Bitomsky N, Hofmann TG. Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2. FEBS J. 2009;276:6074–83.CrossRefPubMed
48.
Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18:3041–54.CrossRefPubMedPubMedCentral
49.
Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;331:713–7.CrossRefPubMed
50.
Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp Cell Res. 2012;318:1285–90.CrossRefPubMed
51.
Hofmann TG, Glas C, Bitomsky N. HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays. 2013;35:55–64.CrossRefPubMed
52.
Sok M, Sentjurc M, Schara M. Membrane fluidity characteristics of human lung cancer. Cancer Lett. 1999;139:215–20.CrossRefPubMed
53.
Mullin JM, Laughlin KV, Ginanni N, Marano CW, Clarke HM, Peralta Soler A. Increased tight junction permeability can result from protein kinase C activation/translocation and act as a tumor promotional event in epithelial cancers. Ann N Y Acad Sci. 2000;915:231–6.CrossRefPubMed
54.
Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. A role for proapoptotic BID in the DNA-damage response. Cell. 2005;122:579–91.CrossRefPubMed
Metadata
Title
p53-independent structure-activity relationships of 3-ring mesogenic compounds’ activity as cytotoxic effects against human non-small cell lung cancer lines
Authors
Saori Fukushi
Hironori Yoshino
Atsushi Yoshizawa
Ikuo Kashiwakura
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2585-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

Research article

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients

Research article

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Research article

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

Research article

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations

Research article

Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits